Star-PROTAC new drug jointly developed by Arvinas and Pfizer (PFE.US) for breast cancer declared for listing

The Zhitong Finance App learned that today, Arvinas and Pfizer (PFE.US) announced that they have submitted a new drug application (NDA) to the US FDA for the treatment of advanced or metastatic breast cancer patients with positive estrogen receptor (ER+) /human epidermal growth factor receptor 2 negative (HER2-) and ESR1 mutations who have previously received endocrine treatment.

According to the press release, if approved, vepdegestrant will be the first proTAC estrogen receptor degrading agent approved by the US FDA. It is worth mentioning that nearly 10 years ago, when such technology was just beginning, Yao Ming Kangde began to lay out relevant capabilities and technology, and accumulated a large number of successful experiences. With the gradual deepening of understanding PROTAC in recent years, the company has built a complete integrated enabling platform for such innovative molecules, integrating discovery, synthesis, analysis, purification, and testing capabilities. Currently, it has successfully supported the development of more than 100 PROTAC molecules, of which more than 20 have successfully advanced to the clinical stage.

Vepdegestrant is a potential “first-in-class” oral PROTAC degrading agent that specifically targets and degrades estrogen receptors using the body's natural proteolytic system. It has been certified as a breakthrough therapy by the US FDA to treat ER-positive and HER2-negative breast cancer.